Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — FY2024 Earnings Presentation
27 slides from Burjeel's earnings presentation, March 2025
Slide 1: Q4&FY2024 Results
March 2025 Q4&FY2024 Results Leading Super-Specialty Healthcare Provider in MENA
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: Key Highlights
Key Highlights Leading Super-Specialty Healthcare Provider in MENA
Slide 4: Strategic Investments Driving Future Growth
Strategic Investments Driving Future Growth Key 2024 Strategic Spendings 2024 Mid-Term Financial Growth Financial Total Revenue Bed Capacity Utilization Ramp-up of Assets Impact • Expanded oncology patient base by growing the medical oncology segment by 40% (low-yield & margin). Revenue • Recruited
Slide 5: Super-Specialty Care Offering Driving Patient Yields
Super-Specialty Care Offering Driving Patient Yields Unmatched Momentum in Scaling Maximizing Patient Growth & Yield Da Vinci Xi system Innovation & Expertise Multi-Organ & Bone Marrow Transplants Liver & Kidney Transplants 32 (100% success rate) Multi-Organ Transplants AED 250,000 – 1,000,000 351 s
Slide 6: 2024: A Landmark Year for Multi-Organ Transplants
2024: A Landmark Year for Multi-Organ Transplants The UAE’s first ABO The UAE’s first pediatric incompatible transplant liver transplant ZERO 16 7 Living Donor Kidney Transplants 16 1 Living Donor Liver Transplants Mortalities and Rejections 9 Deceased Donor 15 Deceased Donor Rejection happens in up
Slide 7: Transforming Cancer Care: The UAE's Leading National Network
Transforming Cancer Care: The UAE’s Leading National Network Burjeel Cancer Institute Diversified Referral Pathways Clinical Governance (Burjeel Medical City) Strengthening Oncology Access & Research Hub for high-end specialized oncology treatments Pathology, AI & Molecular Diagnostics Cancer MDT &
Slide 8: Advancing Women & Children's Healthcare Offering
Advancing Women & Children’s Healthcare Offering Partnered with the "Father of Fetal The UAE’s largest fertility center, Medicine," to provide fetal care for high- which commenced operations in risk pregnancies. First in MENA to September 2024 and became fully perform in-utero spina bifida repair. o
Slide 9: Performance Review
Performance Review Leading Super-Specialty Healthcare Provider in MENA
Slide 10: Delivering Robust Patient Footfall Growth
Delivering Robust Patient Footfall Growth On the Back of Continued Market Penetration Group inpatient footfall, k Group outpatient footfall, k % bed occupancy % OP utilisation 64% 70% 61% 67% 73% 69% 72% 69% • Strong inpatient footfall growth in Q4’24 & FY’24, • Outpatient footfall growth in Q4’24 &
Slide 11: Investment in Network Expansion & Complex Care To Drive Future Revenue Growth
Investment in Network Expansion & Complex Care To Drive Future Revenue Growth & Higher Yields Group Revenue, AED m Group EBITDA, AED m • Top-line growth remained steady in Q4’24, • Q4’24 EBITDA ex-one-offs declined by 28.4% YoY, 1,305 +AED 87m increasing by 7.2% YoY, supported by robust patient foot
Slide 12: Burjeel Medical City Strategically Positioned to Drive High-Yield Patient Growth
Burjeel Medical City Strategically Positioned to Drive High-Yield Patient Growth & Margin Expansion Total patients, k Revenue, AED m1 EBITDA, AED m1 % bed occupancy 54% 68% 48% 62% +18.4% 1,205 +26.3% +21.9% 1,018 539 192 427 157 +16.0% +22.0% +1.3% 326 151 281 49 50 124 Q4’23 Q4’24 FY’23 FY’24 Q4’2
Slide 13: Strategic Investments in Business Expansion to Unlock Significant Growth Potential
Strategic Investments in Business Expansion to Unlock Significant Growth Potential Group OPEX breakdown,1 as % of revenue Group EBITDA analysis, AED m 84.4% 81.2% +87 76.7% 78.1% (39) 12.8% (75) 10.2% 9.4% 9.1% 306 2.3% 2.2% 1.9% 2.1% 290 (53) 25.2% 25.3% Other2 23.8% 24.2% (2) 208 Provision for ECL
Slide 14: Free Cash Flow & Operating Cash Flow Performance
Free Cash Flow & Operating Cash Flow Performance Free cash flow,1 AED m Cash flow from operating activities, AED m % FCF conversion2 64% 42% 51% 51% 566 523 500 497 489 358 366 328 163 2021 2022 2023 2024 2020 2021 2022 2023 2024 AED m 2021 2022 2023 2024 Commentary EBITDA ex-one-offs3 779 878 1,018
Slide 15: Maintaining a Robust Balance Sheet
Maintaining a Robust Balance Sheet AED m FY 2022 FY 2023 FY 2024 Debt maturity as of 31 December 2024 Bank balances and cash 150 170 238 Interest-bearing loans and borrowings 1,261 1,164 1,208 220 215 187 190 Bank overdrafts – – -- 180 Bank debt1 1,261 1,164 1,208 133 Net debt 1,111 994 970 85 2 Lea
Slide 16: Strong Profitability Outlook With Continued Commitment to Dividends
Strong Profitability Outlook With Continued Commitment to Dividends Group net profit analysis, AED m Dividends & Buyback % net profit margin • BoD-Proposed Share Buyback: +475 (526) up to 10% of share capital through open market purchases, fully funded by operating cash flow, subject to shareholder
Slide 17: Growth Plan Guidance
Growth Plan Guidance Leading Super-Specialty Healthcare Provider in MENA
Slide 18: Multi-Pronged Expansion Strategy: Unlock Solid Growth Potential
Multi-Pronged Expansion Strategy: Unlock Solid Growth Potential Key region of focus – UAE & KSA Expansion strategy pillars Expanding World-Class Healthcare Network KSA to drive our geographic expansion 1 Across Emerging UAE Communities Zero-capex expansion into Africa, through O&M contracts Accelera
Slide 19: Expanding Reach, Enhancing Care: Burjeel's Growth Plan across the UAE
Expanding Reach, Enhancing Care: Burjeel’s Growth Plan across the UAE Launch of 1 hospital, The Group will expand its Burjeel-branded network with a hospital, a day surgery center in 1 day surgery center, 11 specialized Dubai and the Northern Emirates, and 11 specialized medical centers across the U
Slide 20: Accelerating Expansion Across Saudi Arabia Through Disruptive Healthcare Innovations
Accelerating Expansion Across Saudi Arabia Through Disruptive Healthcare Innovations PhysioTherabia – 29 Burjeel One – First Day Surgery Center in Riyadh centers launched Performance Upadate1 across 10 cities2 Tabouk • Located in Irqah, Northwestern Riyadh, with an estimated Al Jubail +60% AED 64k v
Slide 21: Ongoing Expansion of Asset-Light O&M Portfolio Drives Bottom-Line Growth
Ongoing Expansion of Asset-Light O&M Portfolio Drives Bottom-Line Growth O&M opportunities in the UAE and MENA 2024 O&M projects FY’24 Al • Stakeholder: ADNOC Group (Corporate) 188,000+ Approach Dhannah • Specifications: Multi-specialty hospital in Al Dhafrah, Abu Dhabi Patient Hospital • Partner wi
Slide 22: Revenue & EBITDA Growth Catalysts for 2025
Revenue & EBITDA Growth Catalysts for 2025 2025 Revenue Growth Drivers (% Contribution): Total Revenue 10% 30% 30% New Expansion Projects 15% 25% BMC & Complex Care Expansion 20% Ramp-up of Centers Opened in 2024 AED 5.0bn Mid-Teens 15% Operations & Maintenance (O&M) Projects 10% Optimization of Exi
Slide 23: Positive Outlook Reiterated
Positive Outlook Reiterated FY 2025 (Expected) Mid-term (2026-2028) • UAE: 1 advanced care oncology center (Dubai), 1 • UAE: 1 hospital (Dubai), 1 day surgery center (Ras Al-Khaimah), 3 Expansion fertility clinic (Al Ain), 6 medical center medical center • KSA: 31 PhysioTherabia centers,1 day surger
Slide 24: Q&A Appendix
Q&A Appendix Leading Super-Specialty Healthcare Provider in MENA
Slide 25: Business model
1 2 Business 1 Differentiating capabilities model • Level I & II Trauma Center • Centralised Lab Serving all • Level III Tertiary NICU • Nuclear Medicine socio-economic • Physio & Rehab Care • Department of Thalassemia groups • Intraoperative MRI • Advanced Center for Research • Da Vinci Xi robotic
Slide 26: Group & Segment Summary
Group & Segment Summary Group financial summary Segmental financial summary2 AED millions Q4’24 Q4’23 FY’24 FY‘23 AED millions Q4’24 Q4’23 FY’24 FY‘23 Revenue 1,305 1,218 5,010 4,535 Revenue 1,305 1,218 5,010 4,535 Inventories consumed (328) (289) (1,269) (1,096) Hospitals3 1,150 1,081 4,406 4,026 D
Slide 27: Investor Relations
Investor Relations March 2025 Sergei Levitskii Director of Investor Relations sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 ir@burjeelholdings.com F: +971 2 2222 363 M: +971 503802383 PO Box 7400, Abu Dhabi, UAE Investor Calendar Company Website